Cleveland, OH 的 肺癌 臨床試驗
26 項針對 肺癌 的研究正在 Cleveland（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Louis Stokes Cleveland VA Medical Center, Cleveland
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
招募中3 期
- Case Western Reserve University, Cleveland
- MetroHealth Medical Center, Cleveland
- UHHS-Chagrin Highlands Medical Center, Beachwood · 距離 10 英里
- 還有 1 項
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- 還有 2 項
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
招募中3 期
- Case Western Reserve University, Cleveland
- Cleveland Clinic Foundation, Cleveland
- UHHS-Chagrin Highlands Medical Center, Beachwood · 距離 10 英里
- 還有 2 項
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- University Hospitals Cleveland Medical Center, Cleveland
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · 距離 12 英里
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor · 距離 22 英里
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
招募中1/2 期
- Cleveland Clinic, Cleveland
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
招募中2 期
- Research Site, Cleveland
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
招募中2 期
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion, Cleveland
- Cleveland Clinic, Cleveland
- Cleveland Clinic - Hillcrest Hospital, Mayfield Heights · 距離 12 英里
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
招募中2/3 期
- University Hospitals Cleveland Medical Center, Cleveland
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
招募中1/2 期
- Case Western Reserve University, Cleveland
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
招募中
- University Hospital Cleveland Medical Center, Cleveland
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- Cleveland Clinic, Cleveland
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
招募中1/2 期
- Case Western Reserve University, Cleveland
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
招募中1 期
- Cleveland Clinic, Cleveland
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
招募中3 期
- University Hospitals Cleveland Medical Center, Cleveland
- The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion, Cleveland
- Cleveland Clinic Foundation, Cleveland
- 還有 1 項
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
招募中3 期
- Case Western Reserve University, Cleveland
- UHHS-Chagrin Highlands Medical Center, Beachwood · 距離 10 英里
- UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor · 距離 22 英里
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
招募中1 期
- University Hospital - Cleveland Medical Center, Cleveland
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
招募中1/2 期
- University Hospitals Cleveland Medical Center, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
招募中觀察性研究
- University Hospitals Seidman Cancer Center, Cleveland
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
招募中
- Louis Stokes VA Medical Center, Cleveland, OH, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
招募中觀察性研究歡迎健康志工
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Mayfield Heights · 距離 12 英里
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
招募中1/2 期
- Cleveland Clinic, Cleveland
其他城市的 肺癌 試驗
- Houston, TX78 項研究
- Boston, MA62 項研究
- New York City, NY60 項研究
- Los Angeles, CA45 項研究
- Arlington, VA41 項研究
- Washington, DC41 項研究
- Chicago, IL41 項研究
- Baltimore, MD40 項研究
- Nashville, TN40 項研究
- St. Louis, MO39 項研究
- Columbus, OH37 項研究
- Philadelphia, PA36 項研究
Cleveland 的其他研究
- 非小細胞肺癌43 項研究
- 癌症（所有類型）36 項研究
- 乳癌35 項研究
- 前列腺癌34 項研究
- 心臟衰竭33 項研究
- 卵巢癌30 項研究
- 轉移性癌症30 項研究
- 大腸直腸癌24 項研究
- 心血管疾病22 項研究
- 子宮內膜癌20 項研究
- 急性髓系白血病20 項研究
- 克隆氏症19 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。